Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
EP 4302750
ORALE DÜNNFILME ENTHALTEND ADRENALIN
granted -
EP 4302751
ORALE DÜNNFILME MIT GERINGER WASSERAKTIVITÄT
granted -
US 11872261
Lipoprotein targeting protease inhibitors and uses
granted -
US 11873350
Dissolution of oxidized cellulose
granted -
US 11873288
Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH)
granted -
US 11872355
Medical device for detecting fluid parameters using fluorescent probes
granted -
US 11872203
Methods of administering solriamfetol to lactating women
granted -
US 11873491
Complement component C5 iRNA compositions and methods of use thereof
granted -
US 11872204
Methods of administering solriamfetol to lactating women
granted -
US 11872312
Neuroprotective liposome compositions and methods for treatment of stroke
granted -
US 11872225
Pyruvate kinase modulators and use thereof
granted -
US 11872244
Thixotropic oxidized cellulose solutions and medical applications thereof
granted -
US 11873319
Cyclic di-nucleotide induction of type I interferon
granted -
US 11873291
Quinoline cGAS antagonist compounds
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11873300
Crystalline forms of CFTR modulators
granted -
US 11873296
Solid forms of a dual RAF/MEK inhibitor
granted -
US 11873495
Compounds and methods for reducing LRRK2 expression
granted -
US 11872092
Methods for surgical guidance in breast cancer surgery and lymph node dissection using two or more implantation devices comprising a capsule and a population of ultrasound-switchable fluorophores incorporated in the capsule
granted -
US 11872200
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
WO 2024015441
EXOSOMES DE LAIT BOVIN POUR L'ADMINISTRATION DE VITAMINE K2 ET L'AUGMENTATION DE LA BIODISPONIBILITÉ
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878049
Mitapivat therapy and modulators of cytochrome P450
granted -
US 11878004
Method for inhibiting Zika virus infection
granted -
US 11879003
Methods for increasing T-cell function
granted -
US 11879034
Functionalization of polymer scaffolds
granted -
US 11878012
Compositions and methods for treating traumatic brain injury
granted -
US 11878064
Nanoparticle/peptide method of blocking potassium channels
granted -
US 11877989
Nutritional supplement containing L-α-glycerophosphorylcholine
granted -
US 11878964
Compositions comprising an urolithin compound
granted -
US 11879016
Chimeric antigen receptor
granted -
US 11878011
Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
granted -
US 11878002
Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted -
US 11878062
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 11878977
JAK inhibitors containing a 4-membered heterocyclic amide
granted -
US 11878023
Compositions and methods for delivering pharmaceutical agents
granted -
US 11878998
Prefusion RSV F proteins and their use
granted -
US 11878961
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
granted -
US 11879017
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 11879019
Dual-enzyme responsive peptides
granted -
AR 127448
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
granted -
CA 3262048
CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF
granted -
US 11883441
Compositions and methods for inhibiting seizures
granted -
US 11884945
Methods for purification of arylsulfatase A
granted -
US 11884920
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
granted -
US 11884746
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 11884932
In vitro production of medial ganglionic eminence precursor cells
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.